You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameDesoxycorticosterone Pivalate
Accession NumberDB01134  (APRD00709)
TypeSmall Molecule

Desoxycorticosterone Pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Deoxycorticosterone PivalateNot AvailableNot Available
Deoxycorticosterone TrimethylacetateNot AvailableNot Available
Deoxycortolone PivalateNot AvailableNot Available
Deoxycortone PivalateNot AvailableNot Available
Deoxycortone TrimethylacetateNot AvailableNot Available
Desoxycorticosterone TrimethylacetateNot AvailableNot Available
Desoxycortone PivalateNot AvailableNot Available
DOCPNot AvailableNot Available
DTMANot AvailableNot Available
SaltsNot Available
Brand names
Cortexone MNot Available
Neodin-DepositumNot Available
PercortenNot Available
Percorten MNot Available
Percorten PivalateNot Available
Brand mixturesNot Available
CategoriesNot Available
CAS number808-48-0
WeightAverage: 414.5775
Monoisotopic: 414.277009704
Chemical FormulaC26H38O4
2-{2,15-dimethyl-5-oxotetracyclo[^{2,7}.0^{11,15}]heptadec-6-en-14-yl}-2-oxoethyl 2,2-dimethylpropanoate
Mass SpecNot Available
KingdomOrganic Compounds
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsKetosteroids; Ketones; Carboxylic Acid Esters; Polyamines; Enolates; Ethers; Aldehydes
Substituents20-keto-steroid; 3-keto-steroid; carboxylic acid ester; ketone; enolate; ether; polyamine; carboxylic acid derivative; carbonyl group; aldehyde
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
IndicationExamined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
PharmacodynamicsUsed to treat adrenocortical insufficiency, desoxycorticosterone pivalate is a mineralocorticoid hormone and an analogue of desoxycorticosterone. It primarily acts on the metabolism of sodium, potassium and water. When the drug is given, there is decreased excretion of sodium accompanied by increased excretion of potassium; the concentration of sodium in the blood is thereby increased whereas that of potassium is decreased. There is a concomitant increase in the volume of blood and extracellular fluids, with a fall in hematocrit. It increases the rate of renal tubular absorption of sodium.
Mechanism of actionDesoxycorticosterone Pivalate binds to the mineralocorticoid receptor. Mineralocorticoids are a family of steroids, secreted by the adrenal cortex, necessary for the regulation of a number of metabolic processes including electrolyte regulation. Desoxycorticosterone pivalate exerts its effect through its interaction with the mineralocorticoid receptor (MR), whereby it reacts with the receptor proteins to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin which results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiological effects seen after administration.
AbsorptionNot Available
Volume of distributionNot Available
Protein binding90%
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9954
Blood Brain Barrier + 0.9553
Caco-2 permeable + 0.6211
P-glycoprotein substrate Substrate 0.6541
P-glycoprotein inhibitor I Inhibitor 0.9048
P-glycoprotein inhibitor II Inhibitor 0.8603
Renal organic cation transporter Non-inhibitor 0.6993
CYP450 2C9 substrate Non-substrate 0.8702
CYP450 2D6 substrate Non-substrate 0.9101
CYP450 3A4 substrate Substrate 0.8098
CYP450 1A2 substrate Non-inhibitor 0.9498
CYP450 2C9 substrate Non-inhibitor 0.8229
CYP450 2D6 substrate Non-inhibitor 0.9356
CYP450 2C19 substrate Non-inhibitor 0.8875
CYP450 3A4 substrate Non-inhibitor 0.8554
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7501
Ames test Non AMES toxic 0.9473
Carcinogenicity Non-carcinogens 0.9159
Biodegradation Not ready biodegradable 0.9231
Rat acute toxicity 1.7883 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9494
hERG inhibition (predictor II) Non-inhibitor 0.7297
  • Novartis pharmaceuticals corp
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental Properties
water solubilityInsolubleNot Available
logP4Not Available
Predicted Properties
Water Solubility0.00141ALOGPS
pKa (Strongest Acidic)17.19ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity117.26 m3·mol-1ChemAxon
Polarizability48.32 Å3ChemAxon
Number of Rings4ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
SpectraNot Available
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
PubChem Compound13126
PubChem Substance46506381
Therapeutic Targets DatabaseDAP001106
Drug Product Database2139227
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(65.5 KB)
Drug InteractionsNot Available
Food InteractionsNot Available


1. Mineralocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist


Name UniProt ID Details
Mineralocorticoid receptor P08235 Details


  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Beaumont K, Fanestil DD: Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  5. Sekihara H, Island DP, Liddle GW: New mineralocorticoids: 5alpha-dihydroaldosterone and 5alpha-dihydro-11-deoxycorticosterone. Endocrinology. 1978 Oct;103(4):1450-2. Pubmed

comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13